Table 3. TACE plus apatinib vs. TACE alone: a meta-analysis of adverse events (AEs) and survival rate.
| Study group | Number of studies | OR (95% CI) | P value | I2 | Heterogeneity P value |
|---|---|---|---|---|---|
| Adverse events | |||||
| Fever | 12 | 1.057 (0.749–1.492) | 0.752 | 21.854 | 0.229 |
| Abdominal pain | 9 | 1.080 (0.748–1.558) | 0.681 | 0 | 0.494 |
| Nausea/vomit | 12 | 1.099 (0.778–1.554) | 0.591 | 1.97 | 0.425 |
| Myelosuppression | 9 | 1.119 (0.682–1.835) | 0.656 | 0 | 0.645 |
| Hypertension | 13 | 10.867 (6.319–18.688) | <0.001 | 82.653 | <0.001 |
| Hand-foot syndrome | 11 | 20.681 (9.399–45.503) | <0.001 | 69.326 | <0.001 |
| Proteinuria | 11 | 9.830 (4.685–20.625) | <0.001 | 61.255 | 0.004 |
| Diarrhea | 12 | 3.375 (1.932–5.897) | <0.001 | 30.243 | 0.15 |
| Oral ulcer | 4 | 3.843 (0.834–17.720) | 0.084 | 45.939 | 0.136 |
TACE, transcatheter arterial chemoembolization.